Table 1.
Specification of tracers
| 89Zr-DFO-trastuzumab | 89Zr-DFO-IgG1 | |||||
|---|---|---|---|---|---|---|
| Random | ß-Gal | EndoS2 | EndoS2-R | Random | EndoS2 | |
| Radiochemical yield (MBq) | 37.4 ± 3.8 | 32.6 ± 4.28 | 23.9 ± 2.19 | 22.7 ± 7.3 | 32.0 | 15.9 |
| Purity TLC (%) | >99 | >99 | >99 | >99 | >99 | >99 |
| Aggregates at EOS (%) | ≤ 5 | ≤ 5 | ≤ 5 | ≤ 5 | ≤ 5 | ≤ 5 |
| Specific activity (MBq/mg) | 279.1 ± 28.11 | 243.3 ± 31.92 | 178.11 ± 16.38 | 169.40 ± 54.48 | 238.8 | 227.1 |
| Immunoreactivity (%) | 80 | 93 | 93 | 82 | - | - |
| Activity injected (MBq) | 2.3 ± 0.04 | 2.2 ± 0.02 | 1.6 ± 0.06 | 2.2 ± 0.1 | 2.1 ± 0.08 | 2.0 ± 0.05 |
| Protein dose injected (µg) | 8.5 ± 0.21 | 8.3 ± 0.18 | 8.9 ± 0.06 | 9.6 ± 0.44 | 8.9 ± 0.36 | 8.9 ± 0.21 |
| Degree of labeling | 0-6 | 4 | 2 | - | - | - |
Values are mean ± SEM